XML 36 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Income taxes
12 Months Ended
Sep. 30, 2021
Income taxes  
Income taxes

9.

Income taxes

The Company recorded an income tax benefit of $1.9 million for the year ended September 30, 2021. The Company recorded provisions for income taxes of $0.4 million and $0.3 million for the years ended September 30, 2020 and 2019, respectively.

The domestic and foreign components of pre-tax loss for the year ended September 30, 2021, 2020, and 2019 are as follows:

Year ended September 30,

(in thousands)

2021

2020

2019

US

    

(149,533)

    

(138,016)

    

(107,847)

Foreign

 

(4,495)

 

(1,533)

 

470

Total

 

(154,028)

 

(139,549)

 

(107,377)

The components of the provision for income taxes for the year ended September 30, 2021, 2020, and 2019 are as follows:

Year ended September 30,

(in thousands)

    

2021

    

2020

    

2019

Current

 

  

 

  

 

  

Federal

 

 

 

State

 

(29)

 

 

108

Foreign

 

108

 

382

 

184

Total Current

 

79

 

382

 

292

Deferred

 

  

 

  

 

  

Federal

 

(2,268)

 

 

State

 

259

 

 

Foreign

 

 

 

Total Deferred

 

(2,009)

 

 

Total Provision

 

(1,930)

 

382

 

292

The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate:

Year ended

    

September 30,

    

2021

    

2020

    

2019

Tax expense computed at the federal statutory rate

 

21

%  

21

%  

21

%

Change in valuation allowance

 

(33)

%  

(25)

%  

(22)

%  

Research and development credit benefit

 

3

%  

1

%  

1

%

Business combination

 

(2)

%  

 

 

Stock-based compensation

 

12

%  

3

%  

Total income tax expense

 

1

%  

%  

%

The significant components of the Company’s deferred tax assets and liabilities are as follows:

    

September 30, 

(in thousands)

    

2021

    

2020

Net operating loss carryforwards

$

163,782

$

112,434

Research and development credit carryforwards

 

20,163

 

9,407

Operating lease liability

 

14,890

 

7,506

Other

 

11,631

 

5,639

Gross deferred tax assets

 

210,466

 

134,986

Less: Valuation allowance

 

(190,428)

 

(127,336)

Net deferred tax assets

 

20,038

 

7,650

Fixed assets

 

(785)

 

(105)

Operating lease right-of-use asset

 

(14,893)

 

(7,498)

Intangible assets

 

(4,360)

 

(47)

Gross deferred tax liabilities

 

(20,038)

 

(7,650)

Total net deferred tax asset

$

$

Based on the available objective evidence, management believes it is more likely than not that the deferred tax assets will not be fully realizable. Accordingly, the Company has provided a full valuation allowance against its deferred tax assets at September 30, 2021 and 2020. The valuation allowance was $190.4 million and $127.3 million as of September 30, 2021, and 2020, respectively. The change in the valuation allowance was mainly due to an increase in the net operating loss and research and development credits during the fiscal year 2021.

The Company intends to continue maintaining a full valuation allowance on the Company’s deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of the allowance. The release of all, or a portion, of the valuation allowance would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period the release is recorded.

As of September 30, 2021, the Company had net operating loss carryforwards of approximately $664.5 million and $377.1 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The net operating losses will begin to expire in fiscal year 2032.

The Company also had federal and state research and development credit carryforwards of approximately $16.9 million and $12.5 million, respectively, at September 30, 2021. The federal credits will expire starting in 2033 if not utilized. The California research and development credits have no expiration date. Utilization of the net operating losses and tax credits is subject to annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitations may result in the expiration of the net operating losses and tax credits before utilization.

The provisions of ASC 740-10, Accounting for Uncertainty in Income Taxes, prescribe a comprehensive model for the recognition, measurement, and presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The Company has identified uncertain tax positions related to federal and state research and development credits and foreign jurisdictions.

The aggregate changes in the balance of gross unrecognized tax benefits are as follows:

Federal

(in thousands)

    

and state

Balance as of September 30, 2018

$

2,249

Increases related to tax positions taken during 2019

 

1,042

Balance as of September 30, 2019

$

3,291

Increases related to tax positions taken during 2020

 

1,409

Balance as of September 30, 2020

$

4,700

Increases related to tax positions taken during 2021

 

2,737

Balance as of September 30, 2021

$

7,437

The Company does not expect a material change in unrecognized tax benefits in the next twelve months. As of September 30, 2021, approximately $0.1 million of unrecognized tax benefit would, if recognized, impact the Company’s effective income tax rate.

It is the Company’s policy to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. The Company’s management determined that no accrual for interest and penalties was required as of September 30, 2021 and 2020.

The Company’s files federal and state income tax returns with varying statutes of limitations. All tax years remain open to examination due to the carryover of net operating losses or tax credits. The Company currently has no federal or state tax examinations in progress.

In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.